BioSpace News Archive

Business

MiNK Therapeutics Reports Second Quarter 2023 Results

MiNK Therapeutics, Inc. today provided a corporate update and reported financial results for the second quarter 2023.

August 10, 2023
·
5 min read
Business

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing and commercializing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three and six months ended June 30, 2023 and provided an operating update.

August 10, 2023
·
21 min read
FDA

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

Genprex, Inc. today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the Company’s lead drug candidate, REQORSA® Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).

August 10, 2023
·
8 min read
Business

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech plc announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.

August 10, 2023
·
13 min read
Business

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Phathom Pharmaceuticals, Inc. reported financial results for the second quarter of 2023 and provided updates on recent regulatory and business progress.

August 10, 2023
·
9 min read
XNK Therapeutics enters into agreement with US-based biotechnology company

XNK Therapeutics AB announced that the company has entered into an agreement with a US biotechnology company.

August 10, 2023
·
2 min read
Policy

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Limited announced that it has received an approval letter from the Nasdaq Stock Market LLC Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market.

August 10, 2023
·
3 min read
Business

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2023, highlighted key recent and upcoming expected milestones, and presented emerging data from its ongoing Phase 2 clinical trial of mavorixafor in people with certain chronic neutropenic disorders.

August 10, 2023
·
14 min read
Biotech Beach

Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provided an update on the ongoing patent infringement case brought against Kurin by Magnolia Medical.

August 10, 2023
·
2 min read
Business

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2023.

August 10, 2023
·
28 min read